The company maintains a debt-to-equity ratio of 0.48, yet its $9.4M asset base remains heavily tied to $593.7K in net PPE, which may limit liquidity during periods of financial distress.
| Total Current Assets | 8.73M | 7.8M | 2.75M |
| Cash & Short-Term Investments | 3.01M | 619.58K | 524.61K |
| Cash Only | 748.72K | 619.58K | 524.61K |
| Short-Term Investments | 2.26M | 0 | 0 |
| Accounts Receivable | 4.71M | 3.72M | 1.7M |
| Days Sales Outstanding | 84.69 | 81.33 | 49.35 |
| Inventory | 559.98K | 933.3K | 190.89K |
| Days Inventory Outstanding | 11.42 | 25.95 | 7.1 |
| Other Current Assets | 400 | 1.27M | 268.98K |
| Total Non-Current Assets | 690.17K | 865.52K | 658.29K |
| Property, Plant & Equipment | 593.73K | 833.69K | 654.26K |
| Fixed Asset Turnover | 34.21x | 20.02x | 19.19x |
| Goodwill | 0 | 0 | 0 |
| Intangible Assets | 96.44K | 31.82K | 4.03K |
| Long-Term Investments | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 |
| Total Assets | 9.42M | 8.67M | 3.41M |
| Asset Turnover | 2.16x | 1.93x | 3.69x |
| Asset Growth % | 8.65% | 154.41% | - |
| Total Current Liabilities | 2.92M | 3.18M | 2.55M |
| Accounts Payable | 1.73M | 1.32M | 1.4M |
| Days Payables Outstanding | 35.23 | 36.78 | 52.08 |
| Short-Term Debt | 371.56K | 215.2K | 62.35K |
| Deferred Revenue (Current) | 124.51K | 191.07K | 268.03K |
| Other Current Liabilities | 0 | 0 | 0 |
| Current Ratio | 2.99x | 2.46x | 1.08x |
| Quick Ratio | 2.80x | 2.16x | 1.00x |
| Cash Conversion Cycle | 60.87 | 70.5 | 4.38 |
| Total Non-Current Liabilities | 1.51M | 1.24M | 271.45K |
| Long-Term Debt | 1.5M | 1.12M | 116.86K |
| Capital Lease Obligations | 6.41K | 117.84K | 154.59K |
| Deferred Tax Liabilities | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 |
| Total Liabilities | 4.43M | 4.41M | 2.82M |
| Total Debt | 2.37M | 2.09M | 691.08K |
| Net Debt | 1.63M | 1.47M | 166.46K |
| Debt / Equity | 0.48x | 0.49x | 1.18x |
| Debt / EBITDA | 1.97x | 0.82x | 0.39x |
| Net Debt / EBITDA | 1.35x | 0.58x | 0.09x |
| Interest Coverage | 1.35x | 19.43x | 44.91x |
| Total Equity | 4.99M | 4.25M | 585.24K |
| Equity Growth % | 17.31% | 626.82% | - |
| Book Value per Share | 0.49 | 0.58 | 0.05 |
| Total Shareholders' Equity | 4.99M | 4.25M | 585.24K |
| Common Stock | 11K | 10K | 6.84K |
| Retained Earnings | 1.5M | 1.53M | 201.39K |
| Treasury Stock | 0 | 0 | 0 |
| Accumulated OCI | 10.82K | -4.86K | -4.34K |
| Minority Interest | 0 | 0 | 0 |
Liquidity and Working Capital
As reported in recent financial statements, HKPD's cash reserves have fluctuated significantly, ending 2025Q4 at $748.7K, which represents a precarious buffer given the company's ongoing operational losses and the high-cost environment of Hong Kong pharmaceutical warehousing that necessitates consistent, reliable access to liquid capital for daily operations.
The current cash position appears insufficient to support sustained operational volatility, especially as the company faces a contraction in its core wholesale business. Investors should monitor the current ratio of 2.99, which may be artificially inflated by inventory levels that could prove difficult to liquidate quickly in a downturn.
Based on HKPD's reported figures, the company maintains a debt-to-equity ratio of 0.48 as of 2025Q4, suggesting that while management has avoided excessive borrowing, the existing $2.4M in debt obligations may become increasingly burdensome if the firm fails to reverse its current trend of negative net income.
The reliance on debt to fund operations in the absence of positive cash flow warrants caution regarding future refinancing risks. The company's ability to service these obligations appears tied to its ability to optimize working capital, which remains highly sensitive to the timing of pharmaceutical inventory turnover.
According to recent SEC filings, HKPD's asset base is heavily weighted toward physical infrastructure, with net PPE of $593.7K as of 2025Q4, indicating that the business model is inherently asset-heavy and requires significant ongoing investment to maintain its specialized pharmaceutical-compliant warehousing capabilities in the Hong Kong market.
The concentration of assets in physical infrastructure suggests that the company lacks the flexibility of a pure-play digital service provider. This capital-intensive nature may continue to pressure margins, as the firm must cover high fixed costs regardless of fluctuations in cross-border pharmaceutical demand.
Financial statements reveal that HKPD's balance sheet is potentially distorted by inventory and receivables, as the $9.4M in total assets is heavily reliant on items that may not be easily converted to cash, posing a significant risk to the company's stated liquidity and overall financial stability.
The discrepancy between reported assets and actual cash on hand suggests that the company's solvency is highly dependent on the rapid turnover of pharmaceutical inventory. If the regulatory environment for cross-border imports shifts, the valuation of these assets may be subject to significant impairment, further weakening the balance sheet.
Quick answers to the most common questions about buying HKPD stock.
As of 2025, Hong Kong Pharma Digital Technology Holdings Limited (HKPD) had total assets of $9.4M including $8.7M in current assets.
Hong Kong Pharma Digital Technology Holdings Limited (HKPD) carries total debt of $2.4M, offset by $3.0M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Hong Kong Pharma Digital Technology Holdings Limited (HKPD) has total shareholders' equity (book value) of $5.0M ($0.49 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Hong Kong Pharma Digital Technology Holdings Limited (HKPD) reported a current ratio of 2.99x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.